目前,NC的确诊可通过使用NUT特异性抗体进行免疫组织化学(IHC)染色或通过检测特征性BRD4::NUTM1融合来实现。抗NUT抗体C52B1通常在睾丸中表达,在阳性染色(≥50% 的肿瘤细胞核)时具有显著的 100% 特异性和 87% 敏感性。然而,仅根据形态学,而没有NUT特异性抗体或分子检测进行确诊,仍存在相当大的挑战。 尽管NC的组...
根据解剖部位和NUTM1融合类型将患者分为以下三个风险组:非胸部原发性NC和BRD3或NSD3-NUTM1融合患者、非胸部原发性NC和BRD4-NUTM1融合患者以及胸部原发性NC和任何NUTM1融合类型患者。非胸部BRD3-和NSD3-NUTM1融合肿瘤患者的总生存率明显长于非胸部原发性BRD4-NUTM1融合肿瘤患者。无论NUTM1融合类型如何,胸部原发...
NUTM1是NUT中线癌家族成员1,是仅在睾丸表达的核蛋白,其功能未知(PMID: 31815119)。NUTM1与BRD4融合(t15;19)通常在鳞状细胞癌的NUT中线亚群中发现(PMID: 12543779),并在软组织肿瘤中有报道(PMID: 29356724),许多其他的NUTM1融合在各种其他类型的肿瘤中也有报道(PMID: 32060986, PMID: 31888756, PMID: 31515871, ...
Although NUT adnexal carcinomas are shown to have metastatic potential, they may behave less aggressively than extracutaneous NUT carcinomas. We report a case of a 59‐year‐old man who underwent a biopsy of a 3‐cm plantar mass, which showed BRD4::NUTM1 fusion. The tumor was a poorly ...
Bromodomain containing 4 (BRD4); Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1; NSD3); NUT midline carcinoma 1 (NUTM1; NUT; C15orf55)Studies in patient-derived cell cultures and in vitro suggest inhibiting NSD3 could be useful for treating NUT midline carcinoma (NMC).SciBX: Science-...